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A B S T R A C T
Background: Stage of cancer at diagnosis is one of the strongest predictors of survival and is essential for po-
pulation cancer surveillance, comparison of cancer outcomes and to guide national cancer control strategies. Our
aim was to describe, for the ﬁrst time, the distribution of cases by stage at diagnosis and diﬀerences in stage-
speciﬁc survival on a population basis for a range of childhood solid cancers in Australia.
Methods: The study cohort was drawn from the population-based Australian Childhood Cancer Registry and
comprised children (< 15 years) diagnosed with one of 12 solid malignancies between 2006 and 2014. Stage at
diagnosis was assigned according to the Toronto Paediatric Cancer Stage Guidelines. Observed (all cause) sur-
vival was calculated using the Kaplan-Meier method, with follow-up on mortality available to 31 December
2015.
Results: Almost three-quarters (1256 of 1760 cases, 71%) of children in the study had localised or regional
disease at diagnosis, varying from 43% for neuroblastoma to 99% for retinoblastoma. Diﬀerences in 5-year
observed survival by stage were greatest for osteosarcoma (localised 85% (95% CI=72%–93%) versus meta-
static 37% (15%–59%)), neuroblastoma (localised 98% (91%–99%) versus metastatic 60% (52%–67%)),
rhabdomyosarcoma (localised 85% (71%–93%) versus metastatic 53% (34%–69%)), and medulloblastoma
(localised 69% (61%–75%) versus metastases to spine 42% (27%–57%)).
Conclusion: The stage-speciﬁc information presented here provides a basis for comparison with other interna-
tional population cancer registries. Understanding variations in survival by stage at diagnosis will help with the
targeted formation of initiatives to improve outcomes for children with cancer.
1. Introduction
Population-based cancer registries have an essential role in re-
porting on childhood cancer in that they provide ‘the whole picture’, as
opposed to results from hospital series that only include a selected
subset of cases or clinical trials that are based on patients treated under
strictly-deﬁned protocols. Data contained in cancer registries are thus
crucial when studying outcomes at the population level to inform
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national cancer control plans. Further, information on cancer stage is
essential for meaningful interpretation of these analyses, for example
when comparing results over time and/or between jurisdictions. Yet for
most countries, data on cancer stage are not available at the population
level which has been identiﬁed as a “fundamental gap in population-
based cancer registries” [1].
This is especially true for childhood cancers, in part because of the
lack of an internationally recognised and uniform set of malignancy-
speciﬁc staging systems suitable for use in cancer registries [2]. In
Australia, as in most of the rest of the world, the only information on
childhood cancer stage is primarily from clinical trials; however, as
these results refer only to eligible trial patients, they are unlikely to
represent the stage distribution or stage-speciﬁc outcomes of all pa-
tients.
The recent release [2], successful testing [3] and international en-
dorsement [4] of the consensus-based Toronto Paediatric Cancer Stage
Guidelines has provided population cancer registries the means, for the
ﬁrst time, to assign childhood cancer stage using consistent staging
systems and rules [5]. Using the Toronto Guidelines, we aimed herein
to assign and report the incident distribution and observed survival by
stage at diagnosis of solid cancers for a population-based sample of
childhood cancer patients in Australia, and to compare this information
with published results from other areas where data were available.
2. Material and methods
A complete register of all childhood cancer cases (< 15 years) di-
agnosed in Australia since 1983 is maintained by the Australian
Childhood Cancer Registry (ACCR). With appropriate ethics and legis-
lative approvals, Australia’s eight State and Territory Cancer Registries
provide information to the ACCR each year on all incident childhood
cancer cases diagnosed nationally. In addition, the ACCR Data Manager
makes regular site visits to the major paediatric oncology hospitals to
collect detailed treatment and other clinical information. The survival
status of patients included in the ACCR is kept up-to-date by annual
matching of the entire cohort against the National Death Index, a da-
tabase that contains a record of every death registered in Australia at
any age.
The study cohort comprised Australian residents who were diag-
nosed under the age of 15 and between the years 2006 and 2014 with
one of the 12 types of solid cancers included in the Toronto Guidelines;
namely ‘medulloblastoma and other CNS embryonal tumours’ (here-
after referred to as medulloblastoma), ependymoma, neuroblastoma,
retinoblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing
sarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sar-
coma, testicular germ cell tumours and ovarian germ cell tumours.
Almost all childhood cancer patients in Australia are treated at one of
nine publicly-funded tertiary children’s hospitals located throughout
the country and the data required for assigning stage at diagnosis were
collected from each of these hospitals.
The Toronto Guidelines incorporate a two-tiered approach to de-
ﬁning stage [2], in which the Tier 2 staging systems are generally the
more detailed and intended for use in higher resource settings. This
study uses the Tier 2 staging deﬁnitions, as summarised in Table 1. Full
details of the Tier 1 and Tier 2 staging criteria for each cancer type are
available elsewhere [2,5].
To assign stage, the required data items were manually extracted
from medical records and recorded in a customised online application
during hospital site visits by ACCR staﬀ. Algorithms within the appli-
cation (formulated directly from the staging rules [5]) were passed over
the raw data and stage was assigned automatically. The staging appli-
cation and algorithms have been extensively tested and validated [3].
Kaplan-Meier estimates of observed (all-cause) survival by cancer
stage were calculated using the cohort method, with follow-up to 31
December 2015. Survival time for each patient accumulated from the
date of diagnosis to either the date of death, the end of the follow-up
period, or ﬁve years after diagnosis, whichever occurred ﬁrst. For pa-
tients who remained alive, censoring was applied either ﬁve years after
diagnosis or at the study end date for those with less than 5 years of
follow-up. The equality of survivor functions by cancer stage were
evaluated using the log-rank test. Stage categories were combined for
some cancers where necessary to allow a somewhat larger pool of cases
when estimating survival. Even so, there were an insuﬃcient number of
cases and/or deaths to stratify survival by stage at diagnosis for epen-
dymoma, retinoblastoma, testicular germ cell tumours and ovarian
germ cell tumours.
The study was approved by 16 independent ethics committees re-
presenting each of the State/Territory cancer registries and major
paediatric treating hospitals in Australia. Analysis was conducted using
Stata/SE version 15.1 for Windows (StataCorp LLC, College Station,
TX).
3. Results
The study cohort included 1760 children who had suﬃcient in-
formation in the medical record to enable Tier 2 stage to be assigned.
These cases represented 94% (N=1878) of patients for whom medical
records were located at one of the in-scope hospitals and 88%
(N=2009) of all Australian children aged< 15 years who were di-
agnosed with one of the 12 types of childhood solid cancers between
2006 and 2014, ranging from 65% for ovarian germ cell tumours and
66% for non-rhabdomyosarcoma soft tissue sarcomas to 96% for re-
tinoblastoma.
As shown in Table 2, the most common cancers in the study cohort
were neuroblastoma (n=383, 22%), medulloblastoma (n=261, 15%)
and Wilms tumour (n=241, 14%). Boys accounted for 53% of the
overall study cohort, varying from 46% for Wilms tumour to 62% for
medulloblastoma (aside from sex-speciﬁc cancers). Median age at di-
agnosis was 3 years, ranging from 1 year old for several cancers in-
cluding neuroblastoma, retinoblastoma and hepatoblastoma up to 12
years old for osteosarcoma. There were no signiﬁcant diﬀerences in the
sex or age composition of the study cohort compared against all chil-
dren with one of the 12 in-scope cancers (52% of all patients being boys
versus 53% of the study cohort and both with a median age of 3 years).
3.1. Cases by stage at diagnosis
Approximately three-quarters (n= 1256, 71%) of the children in
the study had localised or regional disease at diagnosis and the re-
maining 504 children (29%) were diagnosed with metastatic cancer.
This distribution varied widely by the type of cancer; less than half
(43%) of children with neuroblastoma had localised or regional disease
at diagnosis, compared to 95% with ovarian germ cell tumours and 99%
with retinoblastoma (Table 3).
The proportion of neuroblastoma patients diagnosed with localised
or locoregional disease varied according to age, with 58% of patients
under 18 months having localised or locoregional disease versus 31% of
those aged 18 months and over (p < 0.001). Further, of the 70 neu-
roblastoma patients under 18 months at diagnosis who had metastatic
disease, 24 (34%) were classiﬁed as stage MS (i.e. metastases conﬁned
to the skin, liver and/or bone marrow).
Children with Wilms tumour were treated under the COG (post-
operative chemotherapy) or SIOP (pre-operative chemotherapy) pro-
tocols [6], with similar numbers overall in both groups (49% and 51%,
respectively). Although the majority (29 of 42, 69%) of children diag-
nosed with Stage IV Wilms tumours were treated with SIOP protocols,
the diﬀerence in stage distribution by treatment protocol was only of
borderline statistical signiﬁcance (p=0.07).
Just over a quarter (28%) of children with retinoblastoma had bi-
lateral disease; they were more likely to be treated conservatively (focal
therapies or chemotherapy without enucleation being performed, stage
0) than those with unilateral disease (50% and 22%, respectively,
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p=0.001). There was an insuﬃcient number of cases (n= 9) to es-
tablish any pattern in stage distribution for children with bilateral
Wilms tumours. No bilateral cases were recorded for either testicular or
ovarian germ cell tumours.
3.2. Observed survival by stage at diagnosis
A total of 353 deaths (20%) were recorded among patients in the
study cohort to 31 December 2015 (Table 2). Nearly all of these deaths
(n=339, 96%) were related to the original cancer. Children with
medulloblastoma (n=99, 38%), ependymoma (n=30, 29%) and os-
teosarcoma (n= 22, 28%) had the highest proportions of deaths due to
any cause, while in contrast all children in the study cohort with tes-
ticular germ cell tumours and nearly all with either retinoblastoma or
ovarian germ cell tumours remained alive by the end of the study
period.
The largest diﬀerences in ﬁve-year observed survival by stage at
diagnosis were observed for osteosarcoma (85% for localised cases
versus 37% for children with metastatic disease), neuroblastoma (98%
for stage L1 versus 60% for metastatic (excluding stage MS)), rhabdo-
myosarcoma (85% for stage I versus 53% for stage IV), non-rhabdo-
myosarcoma soft tissue sarcoma (89% for stages I and II combined
versus 47% for stage IV) and medulloblastoma (69% for stage M0
versus 42% for stage M3) – see Table 4 and Fig. 1. Among children with
neuroblastoma, the survival estimate of 60% for stage M contrasted
with 5-year observed survival of 92% for stage MS, although the latter
result was based on only a small number of cases (n= 24). Excluding
children under 18 months of age, the estimate for 5-year observed
survival for children with stage M neuroblastoma dropped to 52% (95%
CI= 42%–60%). Smaller, but nonetheless signiﬁcant, diﬀerences by
Table 1
Summary of the staging systems in the Toronto Guidelines by type of solid tumour.
Type of solid tumoura Staging system Stage
category
Summary deﬁnitionb
Ependymoma, medulloblastoma Chang M [7] M0 No visible disease on imaging beyond primary site of disease and no tumour cells in the
CSF.
M1 Tumour cells in the CSF.
M2 Visible metastasis in brain.
M3 Visible metastasis in spine or cervico-medullary junction.
M4 Visible metastasis outside of the CNS.
Neuroblastoma INRGSS [16] L1 Localized tumour that does not involve any vital structures as deﬁned by the list of IDRFs
and
the tumour must be conﬁned within one body compartment (neck, chest, abdomen, or
pelvis).
L2 Locoregional tumour with one or more IDRFs.
MS Metastatic disease conﬁned to skin, liver, and/or bone marrow, in a patient less than 18
months old.
M Distant metastatic disease (not contiguous with the primary tumour) except as deﬁned
for stage MS.
Retinoblastoma IRSS [29] 0 The tumour is conﬁned to the globe and enucleation has not been performed.
I Enucleation with negative margins.
II Enucleation with microscopic residual disease.
III Regional extension.
IV Distant metastatic disease.
Wilms tumour COG/ NWTSG [6] I Tumour limited to kidney and completely resected.
II Tumour extends beyond kidney but completely resected.
III Residual tumour or non-haematogenous metastases conﬁned to abdomen.
IV Haematogenous metastases or spread beyond abdomen at diagnosis.
SIOP [6] yI Tumour limited to kidney and completely resected.
yII Tumour extends beyond kidney but completely resected.
yIII Incomplete excision of the tumour (gross or microscopic extension beyond the resection
margins).
IV Haematogenous metastases or spread beyond abdomen at diagnosis.
Hepatoblastoma, osteosarcoma, Ewing
sarcoma
Localised/ metastatic L Tumour conﬁned to the organ or area of origin, including regional lymph nodes.
M Distant metastatic disease.
Rhabdomyosarcoma Anatomic site and
TNM [30]
I Favourable site, any T, any N, M0.
II Unfavourable site, T1a or T2a, N0, M0.
III Unfavourable site and (T1a or T2a, N1, M0) or (T1b or T2b, any N, M0).
IV Any site, any T, any N, M1.
Non-rhabdomyosarcoma soft tissue
sarcomas
TNM [30] and grade I Any T, N0, M0, G1 or Gx.
II T1, N0, M0, G2 or G3.
III (T2 or T3 or T4, N0, M0, G2 or G3) or (any T, N1, M0, any G).
IV Any T, any N, M1, any G.
Testicular germ cell tumours TNM [30] I Any T, N0, M0.
II Any T, any N, M0.
III Any T, any N, M1.
Ovarian germ cell tumours FIGO [31] I Tumour conﬁned to ovaries (one or both).
II Tumour involves one or both ovaries with pelvic extension (below the pelvic brim).
III Tumour involves one or both ovaries with cytologically or histologically conﬁrmed
spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal
lymph nodes.
IV Distant metastasis (excluding peritoneal metastases).
Abbreviations: CFS = cerebrospinal ﬂuid; CNS = central nervous system; COG = Children’s Oncology Group; IDRFs = image-deﬁned risk factors; INRGSS =
International Neuroblastoma Risk Group Staging System; IRSS = International Retinoblastoma Staging System; G = tumour grade; NWTSG = National Wilms
Tumour Study Group; SIOP = International Society of Paediatric Oncology; TNM = tumour size/regional lymph node involvement/metastasis.
Notes: a. Classiﬁed according to the International Classiﬁcation of Childhood Cancers, version 3 (ICCC-3) [32]. b. For the full deﬁnitions, see https://cancerqld.blob.
core.windows.net/content/docs/childhood-cancer-staging-for-population-registries.pdf.
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stage were also demonstrated for each of the other childhood solid
cancers included in the survival analysis: Ewing sarcoma (91% for lo-
calised versus 73% for metastatic), hepatoblastoma (88% for localised
versus 64% for metastatic) and Wilms tumour (varying from 97% for
stage III/yIII to 83% for stage IV).
4. Discussion
We report here the ﬁrst national study, conducted within the setting
of a population-based childhood cancer registry, describing the incident
distribution and survival by stage at diagnosis for a range of the most
common types of childhood solid cancers. Well over 90% of the eligible
study cohort were able to be staged from ﬁrst principles using the
Toronto Guidelines [5]. Earlier work has demonstrated that only ap-
proximately 40% of childhood cancer cases in Australia have stage
recorded by the treating clinician in the medical record [3]. We found
that around three out of every four children with a solid cancer were
diagnosed at a lower stage and that, when there were a suﬃcient
number of cases, all of these cancers exhibited highly signiﬁcant dif-
ferences in stage-speciﬁc survival. While this latter ﬁnding may be
expected, quantifying the extent of the diﬀerences is nonetheless im-
portant as it demonstrates the capability of the systems included in the
Toronto Guidelines to clearly discriminate survival by stage. Reporting
on outcomes by stage for childhood cancers had not been possible until
now due to the previous lack of information on stage at diagnosis
within the Australian Childhood Cancer Registry, as in most other
cancer registries, thus hampering the interpretation of results.
There is a notable paucity of published information on the stage-
speciﬁc distribution and survival of solid childhood tumours; what is
available comes mainly from clinical trials, with varying eligibility
criteria, and not from population cancer registries, making comparisons
with the present results diﬃcult unless population-level recruitment
rates to the trial are high and there are no stringent eligibility criteria.
Importantly, our study has been conducted within the setting of a po-
pulation-based childhood cancer registry and the results presented here
will provide a comparison point for similar analyses in other countries
as the Toronto Guidelines [5] are implemented more broadly in cancer
registries around the world.
4.1. International comparisons for the distribution of stage at diagnosis
Based on the Chang M staging system [7] that classiﬁes stage ac-
cording to the anatomic location of metastases in the central nervous
system, 44% of children aged 3 to 18 years in a randomised trial for
medulloblastoma in Germany, Austria, and Switzerland had some form
of metastatic disease at diagnosis [8], somewhat higher than the 31%
from our study. This variation may partly reﬂect the diﬀerent age
groups under consideration and also may represent cohort eﬀects. For
instance, the study conducted in Europe reports outcomes for patients
registered between 1991 and 1997 and therefore may not represent the
current situation. The Australian distribution of stage at diagnosis for
Wilms tumour (29% stage I/yI and 17% stage IV) more closely re-
sembled recent results from the United Kingdom (36% and 18%) than
from Germany (55% and 16%), noting that the results for both of these
countries were from an international randomised trial of patients who
were all treated with pre-operative chemotherapy. The trial had high
national recruitment rates however (> 90% for Wilms tumour in the
Table 2
Characteristics of the study cohort by type of solid tumour, Australian

















Total study cohort 1760 87.6 52.7 3 20.1
Ependymoma 102 87.9 57.8 3.5 29.4
Medulloblastoma 261 94.3 61.7 5 37.9
Neuroblastoma 383 91.9 50.7 1 23.2
Retinoblastoma 148 96.1 52.7 1 0.7
Wilms tumour 241 90.6 45.6 3 7.1
Hepatoblastoma 80 93.2 57.5 1 18.8
Osteosarcoma 80 83.3 51.3 12 27.5
Ewing sarcoma 109 92.4 46.8 9 13.8
Rhabdomyosarcoma 159 86.9 55.4 4 22.6
Non-rhabdomyosarcoma
soft tissue sarcomas
124 66.0 54.8 7 22.6
Testicular germ cell
tumours
31 81.6 100.0 1 0.0
Ovarian germ cell
tumours
42 64.6 0.0 11 2.4
Notes: a. Classiﬁed according to the International Classiﬁcation of Childhood
Cancers, version 3 (ICCC-3) [32].
Table 3
Incident distribution of stagea by type of solid tumourb, Australian Childhood
Cancer Registry2006–2014.
Type of solid tumourb Staging categorya
Ependymoma (n= 102) M0 M1 M2 M3 M4
n 92 <5d <5d 6 <5d
% 90.2 -d -d 5.9 -d
Medulloblastoma (n= 261) M0 M1 M2 M3 M4
n 179 5 19 58 0
% 68.6 1.9 7.3 22.2 0.0
Neuroblastoma (n=383) L1 L2 MS M
n 98 67 24 194
% 25.6 17.5 6.3 50.7
Retinoblastomac (n= 148) 0 I II III IV
n 45 99 <5d < 5d < 5d
% 30.4 66.9 -d -d -d
Wilms tumourc (n=241) I/yI II/yII III/yIII IV
n 69 55 75 42
% 28.6 22.8 31.1 17.4
Hepatoblastoma (n=80) L M
n 53 27
% 66.3 33.8
Osteosarcoma (n= 80) L M
n 59 21
% 73.8 26.3
Ewing sarcoma (n=109) L M
n 73 36
% 67.0 33.0
Rhabdomyosarcoma (n= 159) I II III IV
n 52 21 50 36
% 32.7 13.2 31.5 22.6
Non-rhabdomyosarcoma (n= 124) I II III IV
n 58 14 26 26
% 46.8 11.3 21.0 21.0
Testicular germ cell tumours (n= 31) I II III
n 25 <5d < 5d
% 80.7 -d -d
Ovarian germ cell tumours (n= 42) I II III IV
n 21 <5d 13 <5d
% 50.0 -d 31.0 -d
Abbreviations: L = localised; M = metastatic; MS = metastatic disease in
patients aged< 18 months at diagnosis with metastases conﬁned to skin, liver
and/or bone marrow; M0 = no visible disease on imaging beyond primary site
and no tumour cells in the cerebrospinal ﬂuid; M1 = tumour cells in the cer-
ebrospinal ﬂuid; M2 = visible metastasis in the brain; M3 = visible metastasis
in spine or cervicomedullary junction; M4 = metastasis outside of the central
nervous system.
Notes: a. Cases were staged using Tier 2 of the Toronto Paediatric Cancer Stage
Guidelines [2]. b. Classiﬁed according to the International Classiﬁcation of
Childhood Cancers, version 3 (ICCC-3) [32]. c. In cases of bilateral disease,
staging was based on the most advanced side. d. Result withheld (cell count< 5
or insuﬃcient data).
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United Kingdom) and so was likely to represent the stage distribution at
the population level [9]. It was postulated that the smaller proportion
of lower stage tumours in the United Kingdom may reﬂect diﬀerences in
the healthcare system compared to Germany, leading to delays in the
detection of Wilms tumours [9]. Among children with osteosarcoma,
26% in Australia had metastatic disease, similar to contemporary data
from Argentina (31%) [10] but somewhat higher compared to Finnish
children between 1991 and 2005 (18%) [11].
4.2. International comparisons of survival by stage
The ability of Chang’s M staging system to diﬀerentiate survival for
childhood medulloblastoma appears mixed. Dufour et al. [12] did not
ﬁnd a signiﬁcant diﬀerence in survival by stage for children with me-
tastatic medulloblastoma treated at a single institution in France during
the period 1988–2008, with 5-year overall survival of 47%, 51% and
42% for stages M1, M2 and M3, respectively (very similar to our results
of 47% for M1 and M2 combined and 42% for M3). They suggested that
the phenotype of metastasis (nodular or laminar) was a better predictor
of survival than stage [12]. A population-based study of 628 children
diagnosed with medulloblastoma in Canada between 1990 and 2009
also reported a lack of diﬀerence in survival by stage [13]. In contrast,
and reinforcing our ﬁndings, researchers in Switzerland (1972–1991)
[14], Germany (1991–1997) [8] and the United States (1969–1997)
[15] have previously shown a signiﬁcant diﬀerence in survival between
children with non-metastatic and metastatic medulloblastoma based on
a clinical series of patients.
The International Neuroblastoma Risk Group reported 5-year
overall survival of 96% for patients diagnosed at stage L1 and 89% for
stage L2 [16], providing a good match with the outcomes shown here
(98% and 87%, respectively). For children diagnosed with metastatic
neuroblastoma in the United States between 1973 and 2010, 10-year
overall survival was 39% for those aged between 2 and 17 years old at
diagnosis [17], somewhat lower than our result of 52% for 5-year ob-
served survival among children with metastatic disease who were aged
18 months or older. Our ﬁnding of a favourable prognosis for infants
under 18 months old with metastatic neuroblastoma conﬁned to the
skin, liver and/or bone marrow also replicates ﬁndings from other
countries [18–20]. These particular tumours have a tendency to spon-
taneously regress even without chemotherapy; while there are several
plausible genomic, biological and immunological reasons for regres-
sion, the exact mechanisms remain unknown [21,22].
Wilms tumour is treated under either the SIOP or COG protocols,
which diﬀer in the use of neoadjuvant chemotherapy [6]. Both ap-
proaches are used fairly evenly in Australia and were found to achieve
similar survival outcomes. Based on 3559 children treated on the SIOP
2001 protocol for Wilms tumour in Europe from 2001 onwards, Brok
et al. [23] reported 5-year overall survival varied from 98% for stage I
down to 82% for stage IV, corresponding quite well with our results.
A population-based study from the United States [24] on patients
with rhabdomyosarcoma aged 0–19 at diagnosis between 1973 and
2005 found that stage was a strong predictor of mortality, with 5-year
survival ranging from 83% for localised disease to 33% for those with
distant metastases. Survival for children with stage IV rhabdomyo-
sarcoma appeared to be somewhat better within the Australian cohort
at 53%, although our point estimate was accompanied by a wide con-
ﬁdence interval (95% CI=34%–69%) due to the small number of cases
(n= 36). The diﬀerent age criteria in the two datasets combined with
the lower survival experienced by rhabdomyosarcoma patients aged
over 10 years old at diagnosis [24] may also have contributed to this
potential disparity.
We reported a much higher survival rate for localised osteosarcoma
(86%) compared to a recent paper from Argentina (52%), [10] but
consistent with 10-year overall survival in Finland (82%) for the period
1991–2005 [11]. Five-year survival for metastatic stage was also higher
in Australia than for Argentina (37% and 22%, respectively) [10], but
our result was comparable to population data reported in the United
States (1973–2010) and Finland, where 10-year overall survival for
metastatic osteosarcoma was 29% [17] and 36% [11], respectively.
While several childhood solid cancers in this study were char-
acterised by very large diﬀerences in survival between patients with
localised versus metastatic disease at diagnosis, the disparity in survival
by stage at diagnosis (although still statistically signiﬁcant) was
somewhat slighter for children with Wilms tumour, hepatoblastoma or
Ewing sarcoma. A possible reason for the smaller diﬀerence observed in
survival by stage for children with Wilms tumour or hepatoblastoma in
our study may be the higher cure rates for metastatic disease compared
to other solid cancers. For example, the International Childhood Liver
Tumours Strategy Group (SIOPEL) reported that advances in the
treatment regime resulted in 74% of metastatic hepatoblastoma pa-
tients on the SIOPEL-4 trial achieving complete remission at the end of
therapy [25].Trials for Ewing sarcoma have shown that metastatic
disease (especially to bone and bone marrow) has a very poor prognosis
(5-year overall survival< 30%) [26], but the age inclusion criteria for
these trials typically extend into older adolescents and young adults,
which may in part explain the much higher survival (73%) reported
here given that age at diagnosis> 14 years is associated with poorer
prognosis [26].
4.3. Strengths and limitations
A strength of the current study is that it utilises data from the
Table 4
Five-year observed survival estimates by type of childhood solid tumour and
stageb, Australian Childhood Cancer Registry 2006–2014a.






Medulloblastoma M0 179 68.6 (60.8–75.1) < 0.001
M1/M2 24 47.2 (25.7–66.1)
M3 58 42.5 (27.5–56.7)
M4 0 n.a.
Neuroblastoma L1 98 97.7 (91.0–99.4) < 0.001
L2 67 86.5 (73.4–93.4)
MS 24 91.7 (70.6–97.9)
M 194 60.0 (51.8–67.2)
Wilms tumour I/yI 69 93.2 (82.4–97.4) 0.03
II/yII 55 91.3 (78.4–96.6)
III/yIII 75 97.2 (89.1–99.3)
IV 42 83.2 (68.0–91.6)
Hepatoblastoma L 53 87.7 (74.5–94.3) 0.02
M 27 63.9 (41.5–79.6)
Osteosarcoma L 59 85.5 (71.7–92.8) < 0.001
M 21 36.7 (14.8–59.1)
Ewing sarcoma L 73 90.9 (78.7–96.3) 0.02
M 36 72.8 (51.5–86.0)
Rhabdomyosarcoma I 52 85.3 (71.5–92.7) 0.005
II 21 84.4 (58.8–94.8)
III 50 77.6 (62.3–87.4)
IV 36 53.2 (34.2–69.0)
Non-rhabdomyosarcoma soft
tissue sarcoma
I/II 72 89.3 (78.6–94.8) < 0.001
III 26 76.9 (55.7–88.9)
IV 26 46.7 (25.4–65.5)
Abbreviations: L = localised; M = metastatic; MS = metastatic disease in
patients aged<= 18 months at diagnosis with metastases conﬁned to skin,
liver and/or bone marrow.; M0 = no visible disease on imaging beyond pri-
mary site and no tumour cells in the cerebrospinal ﬂuid; M1 = tumour cells in
the cerebrospinal ﬂuid; M2 = visible metastasis in the brain; M3 = visible
metastasis in spine or cervicomedullary junction; M4 = metastasis outside of
the central nervous system; n.a. = not applicable.
Notes: a. Survival was followed up to 31 Dec 2015. b. Type of cancer classiﬁed
according to the International Classiﬁcation of Childhood Cancers, version 3
(ICCC-3) [32]. c. Stage was deﬁned by the Toronto Paediatric Cancer Stage
Guidelines [2]. d. Values shown in brackets are the 95% conﬁdence interval. e.
P-values were derived using the log-rank test.
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Fig. 1. Kaplan-Meier observed survival curves by type of childhood solid tumour and stage, Australian Childhood Cancer Registry, 2006–2014. Survival was followed
up to 31 Dec 2015. Type of cancer classiﬁed according to the International Classiﬁcation of Childhood Cancers, version 3 (ICCC-3) [32]. Stage was deﬁned by the
Toronto Paediatric Cancer Stage Guidelines [2]. Abbreviations: CNS= central nervous sytem; L= localised; M=metastatic; MS=metastatic disease in patients
aged< =18 months at diagnosis with metastases conﬁned to skin, liver and/or bone marrow; M0 = no visible disease on imaging beyond primary site and no
tumour cells in the cerebrospinal ﬂuid; M1 = tumour cells in the cerebrospinal ﬂuid; M2 = visible metastasis in the brain; M3 = visible metastasis in spine or
cervicomedullary junction.
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Australian Childhood Cancer Registry allowing us to report national
population-based estimates of survival. Even so, due to the rarity of
some cancers, the small number of patients available meant conﬁdence
intervals were wide for some of the stage-speciﬁc results. While re-
cognising that other key variables, such as age and treatment received,
might inﬂuence the relationship between stage and survival, the small
numbers available within the various staging categories for most can-
cers in the study preclude multivariable adjustment of survival esti-
mates for other known prognostic factors. Some variation was apparent
in the proportion of patients included in the study by cancer type;
however, the age and sex distribution of the study cohort was essen-
tially the same as that of total eligible patients for all cancer types.
4.4. Conclusions
As the ﬁrst childhood cancer registry to implement the Toronto
Guidelines across a broad range of solid cancers, these results represent
an important step towards consistent and reliable information on stage
for childhood cancers within Australia. Further, they demonstrate that
it is feasible to achieve robust, national population-based information
stratiﬁed by stage. Such data, if available internationally, have the
potential to contribute to improved epidemiological reporting for
childhood cancers globally [27], help to shed light on the factors un-
derlying the marked international inequity in outcomes [28], and in-
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